Exelixis Moves Into RNA-Modifying Cancer Therapy With Storm Pact

 
• By Joseph Haas

Deal Snapshot: In addition to investigating the ADAR1 target with the UK biotech, Exelixis also has optioned a second candidate for non-Hodgkin’s lymphoma under its 2019 deal with Aurigene.

Business partners hands on top of each other symbolizing companionship
Exelixis is building an early-stage cancer pipeline via partnerships

More from Deals

More from Business